Loading...
Loading...
In a report published Friday, BTIG Research analyst Sean Lavin initiated coverage on
AllerganAGN with a Buy rating and $115.00 price target.
In the report, BTIG Research noted, “We are initiating coverage of Allergan Inc. (AGN) with a BUY rating and $115 price target based on 20x 12-24 month adjusted EPS. Consistent double digit earnings growth with nearly all quarterly reports exceeding expectations. Earnings growth alone should move shares higher. Restasis should remain a monopoly in 2014. Any positive updates on DARPin could increase valuation as most investors have likely taken DARPin out of expectations. Any significant increase in the company's dividend or buyback, acquisition of significant growth, and/or a change in tax strategies could move shares higher.”
Allergan closed on Thursday at $96.50.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in